Ligand Pharmaceuticals EBITDA vs. Price To Book
| LGND Stock | USD 116.91 3.40 3.00% |
EBITDA | First Reported 2010-12-31 | Previous Quarter 101.7 M | Current Value 106.8 M | Quarterly Volatility 229.7 M |
For Ligand Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Ligand Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Ligand Pharmaceuticals Incorporated utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Ligand Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Ligand Pharmaceuticals Incorporated over time as well as its relative position and ranking within its peers.
Ligand |
Ligand Pharmaceuticals' Revenue Breakdown by Earning Segment
Check out Correlation Analysis.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.032 | Earnings Share 2.49 | Revenue Per Share 8.509 | Quarterly Revenue Growth 0.576 | Return On Assets 0.013 |
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Ligand Pharmaceuticals Price To Book vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Ligand Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Ligand Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Ligand Pharmaceuticals Incorporated is currently regarded as number one stock in ebitda category among its peers. It is rated below average in price to book category among its peers . The ratio of EBITDA to Price To Book for Ligand Pharmaceuticals Incorporated is about 38,736,910 . At present, Ligand Pharmaceuticals' EBITDA is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Ligand Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Ligand Price To Book vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Ligand Pharmaceuticals |
| = | 101.73 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Ligand Pharmaceuticals |
| = | 2.63 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Ligand Price To Book Comparison
Ligand Pharmaceuticals is currently under evaluation in price to book category among its peers.
Ligand Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Ligand Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Ligand Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Ligand Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Ligand Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -817 K | -857.9 K | |
| Operating Income | 11.9 M | 12.5 M | |
| Income Before Tax | 63.7 M | 66.8 M | |
| Total Other Income Expense Net | 51.7 M | 54.3 M | |
| Net Income | 52.2 M | 54.8 M | |
| Income Tax Expense | 9.8 M | 6.5 M | |
| Net Income From Continuing Ops | 21.1 M | 20 M | |
| Non Operating Income Net Other | -13.8 M | -13.1 M | |
| Net Loss | -38.4 M | -36.4 M | |
| Interest Income | 7 M | 11.2 M | |
| Net Interest Income | 6.3 M | 6.6 M | |
| Change To Netincome | 43.1 M | 45.3 M | |
| Net Income Per Share | 3.02 | 3.17 | |
| Income Quality | 0.95 | 1.00 | |
| Net Income Per E B T | 0.82 | 0.47 |
Ligand Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Ligand Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Ligand Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Ligand Pharmaceuticals' important profitability drivers and their relationship over time.
Use Ligand Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ligand Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ligand Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Ligand Pharmaceuticals Pair Trading
Ligand Pharmaceuticals Incorporated Pair Trading Analysis
The ability to find closely correlated positions to Ligand Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ligand Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ligand Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ligand Pharmaceuticals Incorporated to buy it.
The correlation of Ligand Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ligand Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ligand Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ligand Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Ligand Pharmaceuticals position
In addition to having Ligand Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Tech Funds Thematic Idea Now
Tech Funds
Funds or Etfs that invest in companies involved in research, development, testing, or distribution of technologically based goods and services. The Tech Funds theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
To fully project Ligand Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Ligand Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Ligand Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.